Hemasphere

Article	Citations
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE	159
P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN	92
P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES	56
P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHAN	56
P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY	52
S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)	50
P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC S	50
P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB	48
Embryonic Origins of the Hematopoietic System: Hierarchies and Heterogeneity	44
Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018	43
Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia	35
P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND	31
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study	31
S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS	30
PB2038: THE POTENTIAL MECHANISM OF TCM TREATMENT OF CHRONIC APLASTIC ANEMIA BASED ON DATA MINING AND NETWORK PHARMACOLOGY	30
P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES	30
PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA	28
Metabolic Regulation of Hematopoietic Stem Cells	27
PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS	26
P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA	25
Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-bas	25
S272: SAFETY AND PRELIMINARY PHARMACODYNAMIC EFFECTS OF THE FERROPORTIN INHIBITOR VAMIFEPORT (VIT-2763) IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT BETA THALASSEMIA (NTDT): RESULTS FROM A PHASE 2A STUD	24
P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	24
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Waldenström’s Macroglobulinemia	24
P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)	24

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW	22
P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS	22
S121: MULTIPARAMETER PREDICTION OF MYELOID NEOPLASIA RISK	22
The Impact of Sedentary Lifestyle, High-fat Diet, Tobacco Smoke, and Alcohol Intake on the Hematopoietic Stem Cell Niches	22
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	21
The Promise of Single-cell Technology in Providing New Insights Into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia	21
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	21
5612539 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EP	20
P900: SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE	19
P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY	19
P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	18
PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT	18
P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES	17
P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES	17
P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	16
P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE	16
P1147: SERUM ALBUMIN AND NEUTROPHIL-TO LYMPHOCYTE RATIO TWO INDEPENDENT FACTOR PREDICTING SURVIVAL IN FOLLICULAR LYMPHOMA. MULTI-INSTITUTIONAL 763 COHORT LA	16
P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH R	16
P401: INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD	16
PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE	16
P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01	16
S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE	16
S113: COST OF ILLNESS, EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION FOR SICKLE CELL DISEASE IN GULF COUNTRIES (CESCGU)	15
Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT	15
P1165: PRELIMINARY FINDINGS OF A PHASE Ⅱ STUDY OF CHEMO-FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH-DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA	14
Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19	14
S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK	14
PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA	14
P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.	14
S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT0159955	14
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond	14
PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA	14
P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL S	14
P493: ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC)	14
P932: PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP	14
P1403: SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION TO ACCELERATE IMMUNE RECONSTITUTION AFTER T-CELL DEPLETED ALLOGENEIC HSCT	13
P1254: BASELINE HLA-DR-RESTRICTED NEOANTIGEN BURDEN OF AML BLASTS IMPACTS ON HLA-DR GENE EXPRESSION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT	13
PB2432: MULTIPLE MYELOMA TRANSPLANT DATABASE IN PATIENTS OVER THE AGE OF 65: A SINGLE CENTRE RETROSPECTIVE COHORT ANALYSIS	13
P1653: INFLAMMATION MEDIATED THROMBUS FORMATION IN LYMPHOMAS	13
P1638: CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IS A RISK FACTOR FOR PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH COVID-19.	13
P1085: HISTOLOGICAL TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 48 MONTHS (TOD48) INDICATING AN ADVERSE PROGNOSIS: EVIDENCE FROM TWO POPULATION-BASED COHORTS	13
PB1811: REAL LIFE APPLICATION OF NEXT GENERATION SEQUENCING IN ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE	13
PB1983: RELATIONSHIP BETWEEN REGULAR MOLECULAR MONITORING AND TREATMENT OUTCOMES IN CML PATIENTS IN ARMENIA	13
P1188: DYNAMIC CHANGES IN CIRCULATING EBV-DNA LOAD DURING TREATMENT HAVE PROGNOSTIC VALUES IN EBV+ DLBCL-NOS: A CHINESE COHORT STUDY	12
PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)	12
P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL	12
P421: TARGETED DISRUPTION OF HUMAN FLT3 ERADICATES LEUKEMIC STEM CELLS WITHOUT HARMING HEALTHY HEMATOPOIETIC STEM CELLS	12
PB2148: IMPACT OF OBESITY IN THE CLINICAL OF MULTIPLE MYELOMA PATIENTS: A REPORT FROM MMRF DATASET	12
P351: PROTEASOME INHIBITORS INDUCE DNA DAMAGE AND MITOTIC CATASTROPHE IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) VIA AUTOPHAGY-MEDIATED DEGRADATION OF WEE1	12
P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?	11

P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY	11
P695: SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO TREATMENT WITH DNA DEMETHYLATION AGENT	11
P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA	11
S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.	11
S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY	11
Anchors Away: The Critical Role of Membrane Bound Molecules in Regulating Stem Cell Symmetry	11
P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY	11
P382: A CLINICAL PROGNOSTIC SCORING SYSTEM FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA	10
P1336: LONGTERM EX VIVO EXPANSION OF FUNCTIONAL MURINE AND HUMAN HEMATOPOIETIC STEM CELLS USING BONE-LINING STROMAL CELLS	10
P711: THE PREVALENCE OF FOXP3-E2 ISOFORM IN REGULATORY T CELLS CORRELATES WITH THE DEGREE OF DYSPLASIA IN MYELODYSPLASTIC SYNDROMES	10
P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE ‘OL-ORAL’ ST	10
PB2218: CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE	10
P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL	10
PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE	10
S304: WHAT IS A MASSIVE TRANSFUSION? A SCOPING REVIEW TO INFORM AN INTERNATIONAL CONSENSUS DEFINITION	10
P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE	10
PB2237: HEMATIMETRIC DETECTION OF THE TRIPLICATION OF ALPHA-GLOBIN GENES. THE IMPORTANCE OF YOUR DIAGNOSIS	10
P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION	10
P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.	10
P952: PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER	10
P1243: FUNCTIONAL PRECISION ONCOLOGY FOR FOLLICULAR LYMPHOMA WITH PATIENT-DERIVED XENOGRAFT IN AVIAN EMBRYOS.	10
PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)	10
PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA	10
PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE.	10
P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML	10
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY	9
P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	9
P1463: HEALTHCARE RESOURCE USE, ECONOMIC BURDEN AND IN-PATIENT MORTALITY IN PATIENTS WITH ALPHA- AND BETA-THALASSEMIA COMPARED TO MATCHED CONTROLS IN THE REAL-WORLD SETTING	9
PB2147: CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE	9
P429: THERAPY-INDUCED SENESCENCE TRIGGERS UPREGULATION OF ANTIGEN PRESENTATION VIA PRC2 INHIBITION AND PROMOTES ANTI-TUMOUR IMMUNITY IN ACUTE MYELOID LEUKAEMIA	9
S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA	9
PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	9
P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM	9
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL	9
P1670: MICROPARTICAL-ASSOCIATED THROMBIN GENERATION IN PATIENTS AFTER MILD COVID-19	9
P1392: INTERIM ANALYSIS OF FIRST IN HUMAN PHASE I-II CLINICAL TRIAL OF EX-VIVO GENE THERAPY FOR HURLER SYNDROME: AN UPDATE AT 3 YEAR FOLLOW-UP	9
PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA	9
PB1793: MCL-1 INHIBITION AFFECTS LIPIDOME WHICH MAY BE LINKED TO TUMOR IMMUNITY AND CANCER-RELATED INFLAMMATION IN ACUTE MYELOID LEUKEMIA	9
P949: COMBINATION GA AND MPR VULNERABILITY SCORING TOOLS EFFECTIVELY IMPROVE THE ABILITY TO IDENTIFY THE FRAIL ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	9
PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE	9
P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL	9
P388: THERAPY OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON PEDIATRIC-INSPIRED PROTOCOLS IN THE CZECH REPUBLIC IN 2007–2020	9
P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY	9
PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA	9
P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES	8
P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS	8
P482: ACCUFUSION: A HIGHLY SCALABLE SOFTWARE TOOL FOR DETECTING GENE FUSIONS BY RNA-SEQ IN LEUKEMIA	8
P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS	8
PB2393: ACTIVATION OF ER STRESS AND UNFOLDED PROTEIN RESPONSE (UPR) PATHWAYS IN HEPATITIS B VIRUS (HBV) INFECTED B CELLS AND ITS SIGNIFICANCE IN PATHOGENESIS OF B-CELL NON-HODGKIN LYMPHOMAS (B-NHL)	8
P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND	8
PB2430: EVALUATION OF OUTCOME AND SAFETY PROFILE IN HIGH-DOSE BEAM AND BEEAM CHEMOTHERAPY WITH SUBSEQUENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS – SINGLE-CENTER EXPERIENCE	8
P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHIN	8
P1676: RISK OF DEMENTIA IN OLDER PATIENTS TREATED WITH CHEMOTHERAPY FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY	8
PB1730: PROGNOSTIC VALUE OF EARLY T-ALL IMMUNOPHENOTYPES IN ADULTS ON THE RALL-2016 PROTOCOL	8
P1455: THROMBOEMBOLIC EVENTS IN SPLENECTOMISED VERSUS NON-SPLENECTOMISED THALASSEMIA PATIENTS: A META-ANALYSIS OF OBSERVATIONAL STUDIES	8
PB1835: SHENGMA BIEJIA DECOCTION,A TRADITIONAL CHINESE MEDICINE PRESCRIPTION,INDUCES LEUKEMIA CELLS MITOCHONDRIAL AUTOPHAGY VIA MITOCHONDRIAL DIVISION WAY.	8
P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA	8
PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW	7
P694: INVESTIGATING THE ROLE OF CELL ADHESION MOLECULES IN TUNNELING NANOTUBES FORMATION IN CHRONIC MYELOID LEUKEMIA MICROENVIRONMENT	7
P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.	7
P516: ADULT LANGERHANS CELL HISTIOCYTOSIS WITH THYROID GLAND INVOLVEMENT: CLINICAL PRESENTATION, GENOMIC ANALYSIS AND OUTCOME	7
PB2348: THE PATIENT’S PERSPECTIVE ON CLNICAL TRIALS: RESULTS FROM A REGIONAL SURVEY IN HAEMATOLOGICAL CENTERS IN ANTWERP	7
PB2184: COURSE OF CORONAVIRUS INFECTION IN ONCOHEMATOLOGICAL PATIENTS IN THE POST-TRANSPLANT PERIOD	7
PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA	7
PB1751: ALTERATIONS IN THE GUT MICROBIOME IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH ACUTE LEUKEMIA	7
PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)	7
S269: MACROPHAGE FUNCTIONAL AND METABOLIC REWIRING THROUGH PPAR/PGC1 MODULATION IMPROVES HEME/IRON-DRIVEN DEFECTIVE EFFEROCYTOSIS AND PROMOTES TISSUE DAMAGE RESOLUTION IN SICKLE CELL DISEASE	7
PB2241: CHARACTERISTICS AND OUTCOME OF WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) IN ADULTS: A RETROSPECTIVE ANALYSIS OF 110 TUNISIAN PATIENTS	7
S199: A NATIONAL RETROSPECTIVE COHORT STUDY OF MPN-SVT: RESULTS FROM THE UK MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MASCOT) REGISTRY	7
PB2214: SCD POPULATION SURVEY IN ALBANIA, A PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING DISEASE AND PATIENTS CHARACTERISTICS OF SICKLE CELL DISEASE IN ALBANIAN SCD POPULATION	7
S118: IDENTIFICATION OF DIRECT TRANSCRIPTIONAL TARGET GENES OF NUP98-KDM5A REVEALS REGULATORY NETWORKS IN ACUTE MYELOID LEUKEMIA	7
COVID-19 AND MYELOMA	7
P869: PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM	7
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients	7
P616: THE LOSS OF IΚBΕ INHIBITOR ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA	7
Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial	7
S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION	7
P612: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HAVE DISTURBED FATTY ACID METABOLISM, POSSIBLY CONTRIBUTING TO T-CELL DYSFUNCTION	7
PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)	7
PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS	7

P1301: BIOLOGICAL SIGNIFICANCE OF UCK2 IN HTLV-1-INFECTED CELLS IN ATL LEUKEMOGENESIS AND ACQUIRED RESISTANCE TO AZACITIDINE	7
P1132: PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE	6
P-050: UNDERSTANDING BARRIERS TO AND ENABLERS IN EMPLOYMENT FOR PEOPLE WITH SICKLE CELL DISORDERS IN ENGLAND	6
P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS	6
P1340: RESPONSE RATES AND PROGNOSTIC FACTORS IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE	6
PB2245: CLINICAL CHARACTERISTICS AND RISK FACTORS OF ANEMIA IN PATIENTS WITH SYSTEMIC SCLEROSIS FROM THE PKUPH-SSC COHORT	6
P1392: MACHINE LEARNING ALGORITHM AS A PROGNOSTIC TOOL FOR VENOUS THROMBOEMBOLISM IN ALLOGENIC TRANSPLANT PATIENTS	6
PB1848: NGS AS A FUNDAMENTAL TOOL FOR THE DEVELOPMENT OF NEW TARGETED THERAPIES	6
P624: CHROMOTHRIPSIS IN PATIENTS WITH CLL AND COMPLEX KARYOTYPE: PATTERNS OF ABERRATIONS AND PROGNOSTIC VALUE	6
P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS RE	6
The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation	6
P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY	6
P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML	6
PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY	6
P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY H	6
PB1852: AZACITIDINE COMBINED WITH HAG REGIMEN FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA:PRIMARY ANALYSIS OF A RETROSPECTIVE COHORT	6
P1650: METABOLIC ABNORMALITY AND GLUCOCORTICOID RECEPTOR MODULATION OF MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE THROMBOCYTOPENIA PATIENTS AND AN ACTIVE MURINE MODEL	6
P896: DEVELOPMENT AND VALIDATION OF A FRAILTY PREDICTION MODEL MORE SUITABLE FOR MULTIPLE MYELOMA IN CHINESE PATIENTS: THE TM FRAILTY SCORE.	6
P313: RECURRENT PATHOGENIC GERMLINE CHEK2 VARIANTS IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	6
P628: HIGH THROUGHPUT IMMUNOGENETIC EVIDENCE FOR EXTENSIVE IN VIVO CLASS SWITCH RECOMBINATION EVENTS IN CLL	6
P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY	6
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY	6
P634: MHC-BASED LARGE-SCALE SCREENING FOR ANTI-TUMOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CD8+ T CELLS WITH SPECIFICITY AGAINST THE CLONOTYPIC B-CELL RECEPTOR IMMUNOGLOBULIN	6
P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY	6
P1305: HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM	6
P549: ANALYSIS OF THE CLINICAL SIGNIFICANCE AND PROGNOSTIC IMPACT OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM I1762V IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	6
P1699: ANTITHROMBIN DEFICIENCY IS ASSOCIATED WITH PROTHROMBOTIC FIBRIN CLOT PHENOTYPE	6
S289: MOTIVATORS AND BARRIERS TO BLOOD DONATION AMONG POTENTIAL DONORS OF AFRICAN AND CAUCASIAN ETHNICITY	6
P809: MODULATION OF ARACHIDONIC ACID PATHWAY BY IBUPROFEN RESULTS IN COMPLETE HEMATOLOGICAL RESPONSE IN GHOSAL HEMATODIAPHYSEAL DYSPLASIA WITHOUT NEED FOR CORTICOSTEROID	6
S288: A 9 YEAR REVIEW OF BLOOD TRANSFUSION PRACTICE AND ADHERENCE TO NICE GUIDELINES AT A DISTRICT GENERAL HOSPITAL, UK	6
P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19	6
P473: DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA	6
PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT	6
PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA	6
P1235: GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA	6
P619: TARGETING TRANSLATION BY DISRUPTING THE NEWLY IDENTIFIED PROHIBITIN-EIF4F COMPLEX AS A NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA	6
P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS	6
S172: FUNCTIONAL SUBSETS OF PLASMA CELLS ASSOCIATED WITH AMYLOID PRODUCTION AND	6
P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA	6
PB2284: PROTECTION OF PATIENTS WITH HEMATOLOGIC MALIGNANCY FROM SEVERE INFECTION DURING PANDEMIA: ESTONIAN TWO CENTRES EXPERIENCE	5
PB1804: SLC7A11 IS A POTENTIAL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA	5
P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE	5
P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL	5
PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL	5
P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL	5
PB2219: A REAL-WORLD EXPERIENCE WITH HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON	5
P751: CHARACTERIZING CIRCULAR RNA EXPRESSION IN MYELODYSPLASTIC SYNDROME	5
S259: DUAL ANTIGEN TARGETING WITH CO-TRANSDUCED CD19/22 CAR T CELLS FOR RELAPSED/REFRACTORY ALL	5
P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS	5
PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2	5
P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?	5
P1136: INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING	5
P1483: LONG-TERM IMPACT OF OLIPUDASE ALFA ENZYME REPLACEMENT THERAPY ON SPLEEN VOLUME AND HEMATOLOGIC MANIFESTATIONS IN CHILDREN AND ADULTS WITH CHRONIC ACID SPHINGOMYELINASE DEFICIENCY	5
PB2284: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA	5
PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES	5
P518: VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS	5
P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA	5
P597: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY IN CHRONIC LYMPHOCYTIC LEUKEMIA	5
P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO	5
PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS	5
P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRD	5
P463: RE-PURPOSING OF GENE SIGNATURES IN AML UNCOVERS NOVEL ENERGETICS-ASSOCIATED MOLECULAR SUBTYPES	5
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi	5
P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IF	5
P814: CLINICAL CHARACTERISTICS AND GENE MUTATION ANALYSIS OF 148 CHILDREN WITH FANCONI ANEMIA IN CHINA	5
P475: CONTROL LEUKEMIA BY INDUCING ANTI-CANCER IMMUNE REACTIVITY IN VIVO? POTENTIAL OF A DC-TRIGGERED MECHANISM	5
P431: THE ROLE OF SMARCA4 IN HEMATOPOIESIS AND ACUTE MYELOID LEUKEMIA	5
PB2338: QUALITY OF LIFE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CHRONIC GVHD	5
P1532: CLINICAL OUTCOMES OF COVID-19 IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME (MF/SS)	5
P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE	5
P632: ORAL AND GUT MICROBIAL DIVERSITY CORRELATES WITH PROGNOSTIC FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA	5
PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.	5
P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.	5
P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA	5
P1175: REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE	5
P-053: SICKLE CELL MANAGEMENT AND INTERNATIONAL COOPERATION	5
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA	5
P1400: BOOSTING MITOCHONDRIAL RECYCLING REJUVENATES HEMATOPOIETIC AND IMMUNE SYSTEMS	5
P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY	5
PB1937: UTILITY OF STERNAL BONE MARROW CELL MORPHOLOGY EVALUATION FOR DIAGNOSTIC CATEGORIZATION IN PATIENTS WITH ACQUIRED HYPOCELLULAR BONE MARROW FAILURE SYNDROMES	5
P1208: CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REPORT FROM THE PROSPECTIVE INTERNATIONAL T-CELL LYMPHOMA PROJECT	5
P1496: OPERATOR-INDEPENDENT, FLUORESCENCE-BASED QUANTIFICATION OF POCKED RED CELLS CORRELATES WITH SPLEEN SIZE AND FUNCTION IN SICKLE CELL DISEASE	5
P999: ERK1/2 INHIBITION REDUCES OSTEOPONTIN PLASMA LEVELS AND BONE MARROW FIBROSIS IN A MYELOFIBROSIS MOUSE MODEL	5
S301: GERMAN AMLCG-SURVIVORSHIP STUDY: QUALITY OF LIFE AND LIFE SATISFACTION IN AML LONG-TERM SURVIVORS	5
PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES	5
P1032: REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE	5
P1494: EFFECT OF IRON DEFICIENCY ANEMIA ON PROPRIOCEPTION IN ADULT WOMEN	5
Ferritin Increase in Hemochromatosis Subjects After Discontinuing Their Regular Maintenance Treatment: A Longitudinal Analysis Performed During the COVID-19 Imposed Hospital Lockdown	4
S313: HEALTH ECONOMIC EVALUATION OF THIRD-LINE INTERVENTIONS FOR TRANSPLANT-INELIGIBLE RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GERMANY	4
P-078: HEPATOBILIARY AND SPLENIC COMPLICATIONS OF SICKLE CELL DISEASE IN NIAMEY. A RETROSPECTIVE STUDY FROM 145 PATIENTS	4
P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE	4
P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose	4
P746: COMBINATION OF RAS/MAPK MODULATOR AND AZACITIDINE AFFECTS HISTONE MARKS AND IMPACTS THE INNATE IMMUNE SIGNALING PATHWAY IN THE MDS-L CELL LINE	4
P-070: PLANNING IMPLEMENATION OF PEDIATRIC-TO-ADULT CARE TRANSITION IN SICKLE CELL DISEASE IN BRAZIL	4
P633: ACTIVE CHROMATIN REGULATORY LANDSCAPE OF STEREOTYPED SUBSETS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS A DISTINCTIVE SIGNATURE IN SUBSET #8	4